Palvella Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

• Palvella Therapeutics Inc PVLA.OQ reported a quarterly adjusted loss of 74 cents​​ per share for the quarter ended March 31. The mean expectation of eight analysts for the quarter was for a loss of $1.21 per share. Wall Street expected results to range from $-3.56 to -41 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Palvella Therapeutics Inc's reported EPS for the quarter was a loss of 74 cents​.

• The company reported a quarterly loss of $8.19 million.

• Palvella Therapeutics Inc shares had fallen by 22.5% this quarter and gained 80.8% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 49.5% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Palvella Therapeutics Inc is $49.00

This summary was machine generated from LSEG data May 15 at 01:38 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)